Compare Boston Scientific Corporation (BSX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs PAGSEG Inc — how do they compare? Boston Scientific Corporation trades at $42.6 (market cap $66.37B), while PAGSEG Inc trades at $9.04 (market cap $2.59B). The key difference: Boston Scientific Corporation is far larger — about 25.6× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.21% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | PAGS | |
|---|---|---|
Market Cap | $66.37B | $2.59B |
Sector | Health | Technology |
52-Week High | $108.14 | $12.00 |
52-Week Low | $42.63 | $7.75 |
Enterprise Value | $75.94B | $10.22B |
Dividend Yield | — | 11.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
PAGS trades at $9.28, up 0.32% on the day, with a bullish technical signal from moving averages. The stock shows strong value metrics with a P/E of 6.57 and P/S of 0.68, supported by solid profitability including a 10.4% net income margin. Recent Q1 2026 earnings missed expectations at $0.39 per share versus $0.40 expected, but Q4 2025 beat estimates. The company maintains robust cash flow from operations of $7.56 billion in 2025.
Outlook remains positive due to deep valuation discounts and analyst consensus favoring buys (62.5%). Key risks include Brazilian macroeconomic sensitivity and competitive pressures in digital banking. Upside potential hinges on execution in credit expansion and efficiency gains, with the stock positioned for recovery if rate cuts materialize in Brazil.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
